Nova Pharma Solutions Berhad
Market Cap
RM41.7m
Last Updated
2021/03/04 11:08 UTC
Data Sources
Company Financials
Executive Summary
Nova Pharma Solutions Berhad provides technical documentation, validation, and project execution for pharmaceutical and biotechnology industries in Malaysia, Taiwan, Thailand, and Vietnam. More Details
Risk Analysis
+ 1 more risk
Snowflake Analysis
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Nova Pharma Solutions Berhad's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: Insufficient data to determine NPS's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine NPS's volatility change over the past year.
Market Performance
7 Day Return
0%
NPS
1.0%
MY Construction
0.7%
MY Market
1 Year Return
n/a
NPS
-7.6%
MY Construction
10.2%
MY Market
Return vs Industry: Insufficient data to determine how NPS performed against the MY Construction industry.
Return vs Market: Insufficient data to determine how NPS performed against the MY Market.
Shareholder returns
| NPS | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 1.0% | 0.7% |
| 30 Day | 3.7% | 7.0% | 2.4% |
| 90 Day | n/a | -4.8% | -0.9% |
| 1 Year | n/a | -4.0%-7.6% | 13.7%10.2% |
| 3 Year | n/a | -33.5%-39.2% | -1.8%-10.7% |
| 5 Year | n/a | -29.4%-39.1% | 11.8%-6.6% |
Long-Term Price Volatility Vs. Market
How volatile is Nova Pharma Solutions Berhad's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Nova Pharma Solutions Berhad undervalued compared to its fair value and its price relative to the market?
4.29x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NPS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NPS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NPS is unprofitable, so we can't compare its PE Ratio to the MY Construction industry average.
PE vs Market: NPS is unprofitable, so we can't compare its PE Ratio to the MY market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NPS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NPS is overvalued based on its PB Ratio (4.3x) compared to the MY Construction industry average (0.9x).
Next Steps
Future Growth
How is Nova Pharma Solutions Berhad forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
33.8%
Forecasted Capital Goods industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nova Pharma Solutions Berhad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Nova Pharma Solutions Berhad's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Capital Goods industry.
Past Performance
How has Nova Pharma Solutions Berhad performed over the past 5 years?
-24.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NPS is currently unprofitable.
Growing Profit Margin: NPS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NPS is unprofitable, and losses have increased over the past 5 years at a rate of 24.3% per year.
Accelerating Growth: Unable to compare NPS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NPS is unprofitable, making it difficult to compare its past year earnings growth to the Construction industry (-43.6%).
Return on Equity
High ROE: NPS has a negative Return on Equity (-4.79%), as it is currently unprofitable.
Next Steps
Financial Health
How is Nova Pharma Solutions Berhad's financial position?
Financial Position Analysis
Short Term Liabilities: NPS's short term assets (MYR11.2M) exceed its short term liabilities (MYR1.8M).
Long Term Liabilities: NPS's short term assets (MYR11.2M) exceed its long term liabilities (MYR78.0K).
Debt to Equity History and Analysis
Debt Level: NPS is debt free.
Reducing Debt: NPS had no debt 5 years ago.
Debt Coverage: NPS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NPS has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Nova Pharma Solutions Berhad current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NPS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NPS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NPS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NPS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: NPS is not paying a notable dividend for the MY market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NPS's dividend in 3 years as they are not forecast to pay a notable one for the MY market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.7yrs
Average management tenure
CEO
Boo-Wie Khoo (50 yo)
no data
Tenure
Mr. Khoo Boo Wie serves as Chief Executive Officer and Executive Director of Nova Pharma Solutions Berhad. In year 2005, he joined Nova Pharma as an Engineering and Project Manager. He was promoted to Gene...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | no data | no data | 69.42% MYR 29.0m | |
| Head of Department of Finance | 3.67yrs | no data | no data | |
| Chief Technical Officer & Executive Director | no data | no data | 4.03% MYR 1.7m | |
| Chief Strategy Officer | 3.67yrs | no data | no data | |
| Company Secretary | no data | no data | no data |
3.7yrs
Average Tenure
50yo
Average Age
Experienced Management: NPS's management team is considered experienced (3.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Nova Pharma Solutions Berhad's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Nova Pharma Solutions Berhad
- Ticker: NPS
- Exchange: KLSE
- Founded: 1977
- Industry: Construction and Engineering
- Sector: Capital Goods
- Market Cap: RM41.723m
- Shares outstanding: 149.01m
- Website: https://novapharmasolutions.com
Number of Employees
Location
- Nova Pharma Solutions Berhad
- Sky Park One City
- Suite C-5-1 & 2
- Subang Jaya
- Selangor
- 47650
- Malaysia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| NPS | KLSE (Bursa Malaysia) | Yes | Ordinary Shares | MY | MYR | Mar 2018 |
Biography
Nova Pharma Solutions Berhad provides technical documentation, validation, and project execution for pharmaceutical and biotechnology industries in Malaysia, Taiwan, Thailand, and Vietnam. The company offe...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/04 11:08 |
| End of Day Share Price | 2021/02/23 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.